You are here
Chronic Anemia in CML Patients Responsive to Imatinib
This article is a retrospective, single-institution review of the incidence and clinical characteristics of late chronic anemia associated with prolonged use of imatinib for patients with chronic myeloid leukemia. The authors reported a 30% incidence of late chronic anemia associated with a prolonged use of imatinib, with no effect on overall survival.
The authors reported a 30% incidence of late chronic anemia associated with a prolonged use of imatinib, with no effect on overall survival.
Larger studies are needed to further evaluate the association before a more definitive answer can be determined.
– Jarett Feldman, MD